TISEO, GIUSY
 Distribuzione geografica
Continente #
NA - Nord America 539
EU - Europa 319
AS - Asia 108
AF - Africa 10
SA - Sud America 5
Totale 981
Nazione #
US - Stati Uniti d'America 534
IT - Italia 129
DE - Germania 53
SG - Singapore 49
IN - India 29
NL - Olanda 23
AT - Austria 22
CN - Cina 17
FI - Finlandia 17
IE - Irlanda 14
RU - Federazione Russa 13
GB - Regno Unito 12
SE - Svezia 12
ID - Indonesia 9
TG - Togo 9
FR - Francia 6
CA - Canada 5
UA - Ucraina 5
AR - Argentina 4
BE - Belgio 3
BG - Bulgaria 3
ES - Italia 2
IR - Iran 2
PL - Polonia 2
BD - Bangladesh 1
BJ - Benin 1
BR - Brasile 1
GR - Grecia 1
LT - Lituania 1
PS - Palestinian Territory 1
RO - Romania 1
Totale 981
Città #
Fairfield 81
Rome 48
Seattle 48
Singapore 45
Ashburn 37
Chandler 37
Woodbridge 37
Houston 29
Dearborn 24
Cambridge 23
Wilmington 22
Santa Clara 20
Vienna 17
Naaldwijk 16
Princeton 15
Dublin 14
Helsinki 14
San Paolo di Civitate 12
New York 10
Ann Arbor 9
Jakarta 9
Lawrence 9
Lomé 9
Millbury 8
San Diego 8
Milan 7
Plano 7
Frankfurt am Main 6
Federal 4
Norwalk 4
Andover 3
Beijing 3
Boston 3
Brussels 3
Fremont 3
San Mateo 3
Sofia 3
Amsterdam 2
Des Moines 2
Desio 2
Falls Church 2
La Spezia 2
London 2
Monteriggioni 2
Moscow 2
Nanjing 2
Ottawa 2
Pomezia 2
Seville 2
Toronto 2
Treviso 2
Zanjan 2
Bucharest 1
Caselle Torinese 1
Cotonou 1
Dhaka 1
Falkenstein 1
Florence 1
Gunzenhausen 1
Hefei 1
Hyderabad 1
Jinan 1
Kilburn 1
Kunming 1
Liverpool 1
Matelica 1
Nanning 1
New Bedfont 1
Phoenix 1
Pune 1
Redwood City 1
Reggio Calabria 1
Shanghai 1
Shenyang 1
Shenzhen 1
Stockholm 1
São Paulo 1
Thessaloniki 1
Varese 1
Xiamen 1
Zhengzhou 1
Totale 709
Nome #
Nursing home residence is associated with spread of Clostridium difficile ribotype 027 in central Italy 123
Risk factors for recurrence in patients with Clostridium difficile infection due to 027 and non-027 ribotypes 109
Pharmacokinetics, pharmacodynamics and clinical efficacy of dapagliflozin for the treatment of type 2 diabetes 101
Assessment of risk factors for candidemia in non-neutropenic patients hospitalized in Internal medicine wards. a multicenter study 88
Interplay between Nox2 activity and platelet activation in patients with sepsis and septic shock. a prospective study 83
null 77
Comparison of thrombotic events and mortality in patients with community-acquired pneumonia and COVID-19. a multicenter observational study 77
Spread of hypervirulent multidrug-resistant ST147 Klebsiella pneumoniae in patients with severe COVID-19: an observational study from Italy, 2020-21 52
null 49
The relationship between cardiac injury, inflammation and coagulation in predicting COVID-19 outcome 48
Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study) 46
null 45
Impact of initial antifungal therapy on the outcome of patients with candidemia and septic shock admitted to medical wards. A propensity score-adjusted analysis 41
Risk factors and outcomes of endocarditis due to non-HACEK Gram-negative bacilli: data from the prospective multicenter SEI cohort 38
Fatal fungemia by biofilm-producing Trichosporon asahii in a liver transplant candidate 19
Compassionate use of meropenem/vaborbactam for infections caused by kpc-producing Klebsiella pneumoniae. A multicentre study 19
Ceftazidime-avibactam use for Klebsiella pneumoniae carbapenemase-producing k. pneumoniae infections. A Retrospective observational multicenter study 17
Estimated pulse wave velocity improves risk stratification for all-cause mortality in patients with COVID-19 14
Pharmacokinetic drug evaluation of avibactam + ceftazidime for the treatment of hospital-acquired pneumonia 14
Predicting resistant etiology in hospitalized patients with blood cultures positive for Gram-negative bacilli 9
Totale 1.069
Categoria #
all - tutte 3.601
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.601


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202097 0 0 0 0 0 0 23 19 19 17 6 13
2020/2021101 5 8 1 0 1 4 18 6 9 35 11 3
2021/2022168 5 4 8 9 12 11 8 18 18 6 42 27
2022/2023201 32 41 9 18 29 11 6 13 15 3 15 9
2023/2024149 12 13 10 30 5 16 11 14 7 8 10 13
2024/2025118 6 11 20 17 34 30 0 0 0 0 0 0
Totale 1.069